This ongoing study uses minimal residual disease analysis at two follow-up points, to facilitate risk-adapted treatment stratification in ALL patients aged 1–18 years. In the current analysis ...

"This is important because a competing reaction converts 6-mercaptopurine to the active metabolites that are responsible for ...